Abstract: Combinations of boron compounds and adjuvants and compositions thereof are suitable for use in a method to induce myotube formation and suppress cell mortality in a mammal in need thereof and for the treatment of epithelial cancers. Compositions comprise boron compounds, adjuvants and support platforms, which enhance the effect of synergistic activation of the boron cell membrane transporter (NaBC1) and adhesion receptors in cells. The combinations and compositions are for the treatment of pathophysiological condition, which affects skeletal muscle, such as dystrophy and epithelial cancer. The combinations and compositions can be included in the field of medical chemistry or pharmacology.

Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in mammalian cells to provide gene therapy for pyruvate kinase deficiency.

Abstract: The present disclosure provides gene constructs containing a nucleic acid sequences encoding a mammalian s-KL, operatively linked to a muscle cell-specific promoter, for use in the treatment of motor impairment that may manifest, for example, in a neuromuscular disorder or disease, utilizing viral and non-viral vectors with muscle cell and motor neuron tropisms containing gene constructs containing a nucleic acid sequence encoding a mammalian s-KL, operatively linked to a promoter such as a muscle cell-specific promoter, is delivered in pharmaceutical compositions containing the expression vector, isolated cells containing the expression vector, and methods of treating motor impairment and motor neuron diseases.

Abstract: The present invention proposes a novel method for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients, based on mass spectrometry-based methods, in particular based on multiple reaction monitoring targeted mass spectrometry (MRM-MS). Such methods allow quantification of histones using an internal standard and show strong specificity and sensitivity values.

Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in mammalian cells to provide gene therapy for pyruvate kinase deficiency.

Abstract: Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+cells are provided as well.

Abstract: The present invention refers to a method for exfoliating and transferring graphene from a doped silicon carbide substrate to another substrate, the method being based on exfoliation induced by hydrogen bubbles produced in the electrolysis of water.

Abstract: The invention relates to protein particles comprising a cluster of one or more types of assembled self-contained protein, wherein the particle has a size from 50 nm to 50 micrometers; is in form of a pellet in aqueous media; is mechanically stable; and it release a particular percentage by weight of the self-contained protein within a predetermined period of time, and any other compound contained in the particle. Particular methods for obtaining the particles are also disclosed, said methods comprising the addition of salts to allow precipitation of proteins. Particular protein particles comprising lipids associated with the assembly of self-contained proteins are also disclosed. The invention also relates to several uses of the particle, in particular medical uses and to pharmaceutical and cosmetic compositions comprising the particles.

Abstract: The present invention provides a composition comprising one or more deoxyribonucleosides for use in the treatment of a mitochondrial DNA depletion and/or multiple deletions syndrome provided that the syndrome is not caused by a defect in the deoxyribonucleoside triphosphate (dNTP) metabolism. With the use of the invention there is a recovery in mitochondrial DNA levels independently from the severity of the patient's disease, which confers a great therapeutic value to the invention.

Abstract: It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

Abstract: Specifically, the invention describes obtaining a new porous material prepared to recognise DNA of the pathogenic microorganism Candida albicans, as well as the use thereof in a quick and highly sensitive in vitro diagnostic method.

Abstract: A graphene transistor system for measuring electrophysiological signals uses flexible epicortical and intracortical arrays of graphene solution-gated field-effect transistors (gSGFETs) to record infraslow signals alongside signals in the typical local field potential bandwidth. The graphene transistor system includes a processing unit, and at least one graphene transistor (gSGFET) a tunable voltage source connected to the drain and source terminals of the transistor (gSGFET), and at least one filter configured to acquire and split the signal from the transistor into at least a low frequency band signal and high frequency band signal, which are amplifiable with a gain value.

Abstract: The present invention relates to a novel microfluidic device and a microfluidic system for culturing cell samples based on: one or more culture wells (2) forming cell housing volumes for three-dimensional cell culture; one or more capillary channels (1) for circulating cells and/or fluid media, said channels (1) being connected to the wells (2) as well perfusion means; and an inlet port (3) and an outlet port (3?) for seeding cells and/or for circulating fluid in said channel (1), said ports (3, 3?) being connected to the ends of each capillary channel (1). The novel configuration of the ports (3, 3?) and their corresponding channels (1) allows known microfluidic perfusion media to be improved, dispensing with the use of complex elements for injecting the fluid media, such as syringe pumps, for example. The invention also allows two-dimensional and three-dimensional culture studies to be performed simultaneously.

Abstract: The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hs

Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in mammalian cells to provide gene therapy for pyruvate kinase deficiency.

Abstract: The present invention provides a method for diagnosing or detecting Idiopathic Scoliosis, in particular AIS, as well as a method for prognosticating this disease in a human subject.

Abstract: The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.

Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.

Abstract: Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+ cells are provided as well.

Abstract: The present invention provides a method for predicting subject's responsiveness to a corticosteroid medical regimen, prior to the start of the medical regimen, the method comprising the step of determining the amount of miR218-5p in an isolated test sample of the subject, wherein if no miR218-5p amount is present in the sample, it is indicative that the subject will be responder to the medical regimen, and if miR218-5p is detected in the test sample it is indicative that the subject will not respond to the medical regimen. The invention also provides the use of means for determining the amount of miR218-5p for predicting subject's responsiveness to a corticosteroid medical regimen.